Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment in 2025
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Optimized Maintenance Study Treatment
View:
Post by Eoganacht on Apr 30, 2021 11:55am

Optimized Maintenance Study Treatment

Theralase has confirmed that 2 patients have recieved the optimized maintenance study treatment in study 2.

This number was inadvertently left blank on page 6 of the MD&A.
Comment by enriquesuave on Apr 30, 2021 12:50pm
I was under the impression that 4 of the 1st set of 12 were due to get a second treatment which was  to be an Optimized Procedure, plus all patients from 13 and on.  It will all be clear when we have enough patients who have received at least one or 2 optimized treatments and see the CR rate for this group.  So far 2 on 2 from PH1 and 2 on 3 from PH2  for patients 13,14 & ...more  
Comment by enriquesuave on Apr 30, 2021 12:56pm
  Only patients 5 & 6 got optimized treatment in PH1 and were CR for at least 18 months.  From PH1 "As previously reported, the Company, in conjunction with its clinical partner, have optimized the clinical procedure of the Study commencing with patient number five, who was enrolled and treated in January 2018. The treatment was well tolerated by the patient, who demonstrated no ...more  
Comment by DJDawg on Apr 30, 2021 1:36pm
Thanks for you great post Enrique. So informative. I think I saw in an old thread that a family member of yours was a urologist. Is that correct? What does an industry insider (so to speak) think about the state of BCG unresponsive NMIBC? There is a ton of online excitement about SESN but all my reading suggests that it is treatment intensive and 12 CR is something like 17%.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed in 2025, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250